Dermapharm Holding SE

As of June 30, 2026, Dermapharm Holding SE carries a market capitalization of 2.33B, placing it among publicly traded companies globally. Its enterprise value stands at 3.27B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Dermapharm Holding SE's next confirmed earnings release is scheduled for November 12, 2026.

As of June 30, 2026, Dermapharm Holding SE has 49.54M shares outstanding.

As of June 30, 2026, Dermapharm Holding SE trades at a trailing price-to-earnings ratio of 16.91. The price-to-sales ratio is 2.10, and the price-to-book ratio stands at 4.34.

As of June 30, 2026, Dermapharm Holding SE trades at an EV/EBITDA multiple of 8.55 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 2.77 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 12.67 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. Dermapharm Holding SE trades at an EV/FCF ratio of 12.98, comparing the total takeover cost of the business to the cash it actually generates for all capital providers. These enterprise value multiples are built on an enterprise value of 3.27B versus a market cap of 2.33B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Dermapharm Holding SE maintains a current ratio of 1.71, meaning it holds 1.7x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 219.34, indicating elevated leverage, while an interest coverage ratio of 8.04 demonstrates adequate ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Dermapharm Holding SE posted a return on equity (ROE) of 25.60, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 11.53 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 6.69, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 11.06, useful for judging operating efficiency across full business cycles. The company generates approximately 335,146.67 in revenue per employee across its workforce of 3,525.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 1.04 indicates how many times Dermapharm Holding SE sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Dermapharm Holding SE recorded 47.23M in income tax expense. That works out to an effective tax rate of 24.50, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 192.77M, leaving 146.54M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 22, 2026, Dermapharm Holding SE's stock has gained approximately 17.40% over the past 52 weeks. The 50-day moving average sits at 38.96, while the 200-day moving average is 41.81.

Over the twelve months ended June 30, 2026, Dermapharm Holding SE generated 1.18B in revenue and converted that into 146.54M in net income, yielding earnings per share of 2.76. EBITDA reached 382.64M, while operating income came in at 264.75M.

As of June 30, 2026, Dermapharm Holding SE holds 223.58M in cash and equivalents against 1.17B in total debt, resulting in a net debt position of 949.89M. Total book value stands at 536.71M, with working capital of 317.61M providing operational flexibility.

Dermapharm Holding SE produced 264.34M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -48.39M in capital expenditures, free cash flow totaled 215.96M - equivalent to 4.10 per share.

Over the twelve months ended June 30, 2026, Dermapharm Holding SE posted a gross margin of 68.14, reflecting its pricing power and cost economics. The operating margin of 22.41 and net profit margin of 12.40 provide insight into operational efficiency.

Over the twelve months ended June 30, 2026, Dermapharm Holding SE paid dividends of - - per share. The dividend payout ratio of - - indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Free cash flow yield stands at 8.71, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield reaches 5.64, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Dermapharm Holding SE shareholders.

As of June 30, 2026, Dermapharm Holding SE has an Altman Z-Score of 3.36, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.